Home Apoptosis RIP kinase

RIP kinase Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S6078 ICCB-19 hydrochloride ICCB-19 hydrochloride is an inhibitor of TNFRSF1A Associated Via Death Domain (TRADD) with IC50 of 1.12 μM and 2.01 μM for protecting Velcade-induced apoptosis in Jurkat cells and protecting RDA in MEFs, respectively. ICCB-19 indirectly inhibits Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). ICCB-19 effectively induces autophagy.
EMBO J, 2025, 10.1038/s44318-025-00561-7
Cell Death Discov, 2023, 9(1):109
S8927 GSK2983559 (compound 3) GSK2983559 (compound 3, RIP2 kinase inhibitor 1, RIPK2-IN-1) is a potent inhibitor of receptor interacting protein 2 (RIP2) kinase with good kinase specificity.
Aging (Albany NY), 2021, 13(7):10450-10467
Cancer Research on Prevention and Treatment, 2020, (7): 492-497
S8787 GSK'547 GSK'547 is a highly selective and potent inhibitor of RIP1 (RIPK1) exhibiting a 400-fold improvement in mouse pharmacokinetic oral exposure compared with GSK'963
J Neuroinflammation, 2022, 19(1):109
S8845 GSK3145095 GSK3145095 is a potent and orally active RIP1 kinase inhibitor with IC50 of 6.3 nM with potential antineoplastic and immunomodulatory activities.
EMBO Rep, 2025, 10.1038/s44319-025-00558-7
S8169 GSK481 GSK481 is a RIP1(Receptor Interacting Protein Kinase1, RIPK1) inhibitor. Inhibition of this compound has been shown to hinder cell necrotic death.
J Oncol, 2022, 2022:2390078
E2822 GSK2983559 active metabolite GSK2983559 active metabolite is an active metabolite of GSK2983559, also is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
E2367 PK68 PK68 is a potent orally active and specific inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM.
E5857New GSK-872 hydrochloride GSK-872 hydrochloride is an inhibitor of RIPK3, which binds the RIP3 kinase domain with an IC50 of 1.8 nM and inhibits kinase activity with an IC50 of 1.3 nM. It exhibits the potential in alleviating early brain injury by inhibiting neuronal necroptosis and HMGB1-mediated inflammation.
E0301 Necrostatin-34 (Nec-34) Necrostatin-34 (Nec-34) is a small molecule inhibitor of RIPK1 kinase with an IC50 of 0.13 μM in L929 cells.
E4640New Oditrasertib Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.
E2648 RIPK1-IN-7 RIPK1-IN-7 is a potent and selective receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM.
E1734 OD36 OD36 is an inhibitor of RIPK2 with an IC50 value of 5.3 nM. This compound is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket.
S3443New GSK-843 GSK-843 (GSK'843) is a selective inhibitor of receptor-interacting protein kinase 3 (RIP3 or RIPK3) that binds to the RIP3 kinase domain with an IC50 of 8.6 nM and effectively inhibits its enzymatic activity with an IC50 of 6.5 nM.
S2805 LY364947 LY364947 (HTS 466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM in a cell-free assay, shows 7-fold selectivity over TGFβR-II.
Adv Sci (Weinh), 2024, 11(4):e2304987
Cell Rep Med, 2024, 5(2):101416
Cell Commun Signal, 2024, 22(1):242
Verified customer review of LY364947
S9786 Tuxobertinib (BDTX-189) BDTX-189 (Tuxobertinib) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. This compound exhibits anticancer activity.
Chem Biol Interact, 2024, 395:111033
J Transl Med, 2023, 21(1):89
S5584 Citronellol Citronellol (Dihydrogeraniol, (±)-β-Citronellol), a constituent of rose and geranium oils, is used in perfumes and insect repellents. This compound can cause necrotic apoptosis of NCI-H1299 cells by up-regulating TNF-α, RIP1 / RIP3 activities, and down-regulating caspase-3 / caspase-8 activities. It also results in a biphasic increase in ROS production at 1 h and at 12 h in NCI-H1299 cells.